Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?

Inflamm Bowel Dis. 2019 Sep 18;25(10):e120. doi: 10.1093/ibd/izz153.
No abstract available

Keywords: biosimilar; inflammatory bowel disease; reverse switch.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Biosimilar Pharmaceuticals / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / pathology
  • Drug Substitution / statistics & numerical data*
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab / therapeutic use*
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Biosimilar Pharmaceuticals
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab